1. Home
  2. PED vs IFRX Comparison

PED vs IFRX Comparison

Compare PED & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pedevco Corp.

PED

Pedevco Corp.

HOLD

Current Price

$0.57

Market Cap

49.1M

Sector

Energy

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.07

Market Cap

86.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PED
IFRX
Founded
N/A
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.1M
86.0M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PED
IFRX
Price
$0.57
$1.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$1.50
$8.50
AVG Volume (30 Days)
148.3K
6.5M
Earning Date
11-17-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
156.43
N/A
EPS
0.11
N/A
Revenue
$33,244,999.00
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
$305.89
$1,075.42
P/E Ratio
$5.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.71
52 Week High
$1.00
$2.77

Technical Indicators

Market Signals
Indicator
PED
IFRX
Relative Strength Index (RSI) 53.89 42.52
Support Level $0.43 $1.04
Resistance Level $0.55 $1.12
Average True Range (ATR) 0.04 0.10
MACD 0.01 -0.01
Stochastic Oscillator 93.12 37.16

Price Performance

Historical Comparison
PED
IFRX

About PED Pedevco Corp.

PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: